NEWSROOM

Biotechnology

PRISM MarketView – Bio Investor Alert

PRISM MarketView – Bio Investor Alert

Apr 18, 2024

New York, N.Y., April 18, 2024 - PRISM MarketView - More than 83,000 new cases of bladder cancer are diagnosed in the US each year, and the illness is responsible for around 17,000 deaths annually. Urothelial carcinoma accounts for 90% of bladder cancers in the US and western Europe, and surgery, followed by chemotherapy or radiation is the current standard of care. There are 24 drugs approved by the FDA for bladder cancer, but due to invasive and life-changing surgical procedures, researchers...

Digital Utilities Ventures Completes Strategic Merger – Paving the Way for Future Growth and Innovation

Digital Utilities Ventures Completes Strategic Merger – Paving the Way for Future Growth and Innovation

Apr 18, 2024

Mankato, Minnesota, April 18, 2023 - Digital Utilities Ventures, Inc. (OTC: DUTV) is pleased to announce the successful completion of its acquisition of Easy Energy Systems Technologies, LLC and Easy Modular Manufacturing, Inc. The consummation of this transaction is a significant step forward in DUTV's mission to leverage disruptive modular technologies for addressing global challenges. Mark K. Gaalswyk, the visionary CEO behind this initiative, will lead the newly consolidated entity,...

Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise

Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise

Apr 17, 2024

The new oncology committee will include: Jason Hafron, MD, DDS, PhD, MPH; and Pradeep Tyagi, PhD, MBA Pittsburgh, PA, April 17, 2024 - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company, today announced the expansion of its Scientific Advisory Board to include oncology expertise. The new committee members are: Jason Hafron, MD, DDS, PhD, MPH, the Chief Medical Officer at Michigan Institute of Urology, and Professor of Urology at the...

PRISM MarketView – Biotech Breakfast

Apr 15, 2024

Mobile-Health Network Solutions (MNDR) IPOs; Q32 Bio Surges; EMA Concludes GLP-1 Drugs Not Associated with Suicidal Thoughts New York, N.Y., April 15, 2024 - PRISM MarketView - Healthcare equities finished lower on Friday, in line with broad declines across the market. The S&P 500 Healthcare Index closed down (1.52%) versus the S&P 500 Index which lost (1.46%) and the XBI settled down (3.43%). The European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee concluded...

ONCOCYTE REPORTS Full Year 2023 FINANCIAL RESULTS

ONCOCYTE REPORTS Full Year 2023 FINANCIAL RESULTS

Apr 12, 2024

Conference Call on Friday, April 12, 2024 at 5:00 a.m. PT / 8:00 a.m. ET IRVINE, CA, April 12, 2024 - Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the year ended December 31, 2023. Recent Highlights Bio-Rad Laboratories, Inc. commercial partnership for transplant monitoring IP $15.8 million in gross proceeds received from private placement offering $4.4 million and $3.8 million Q4 2023 and est. Q1 2024 cash burn, respectively...

ONCOCYTE REPORTS Full Year 2023 FINANCIAL RESULTS

Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules

Apr 11, 2024

IRVINE, CA, April 11, 2024 - Oncocyte Corporation (NASDAQ: OCX), (“Oncocyte” or the “Company”), a precision diagnostics company, today announced that it has entered into definitive securities purchase agreements (the “Purchase Agreements”) for the purchase and sale of an aggregate of 5,077,387 shares of common stock, at a purchase price of $ 2.9164 per share of common stock, and pre-funded warrants to purchase 342,888 shares of common stock at a purchase price of $2.9163 per pre-funded warrant...

ONCOCYTE REPORTS Full Year 2023 FINANCIAL RESULTS

Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay

Apr 11, 2024

- Bio-Rad expects to make equity investment in support of deal - Agreement provides for global exclusivity in transplant monitoring commercialization - Bio-Rad granted subsequent investment option upon FDA clearance IRVINE, CA, April 11, 2024 - Oncocyte Corporation (NASDAQ: OCX), a precision diagnostics company, today announced a partnership agreement with Bio-Rad Laboratories (NYSE: BIO), a global leader in life science research and clinical diagnostics products, for the...

ONCOCYTE REPORTS Full Year 2023 FINANCIAL RESULTS

ONCOCYTE TO ANNOUNCE FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS 

Apr 9, 2024

Conference Call and Webcast on Friday, April 12, 2024, at 5:00 a.m. PT / 8:00 a.m. ET IRVINE, CA, April 09, 2024 - Oncocyte Corporation (NASDAQ: OCX), a precision diagnostics company, announced today that the company will release its fourth quarter and full year 2023 financial results on Friday, April 12, 2024, prior to the U.S. market open. The company will host a conference call and webcast on Friday, April 12, 2024, at 5:00 a.m. Pacific Time / 8:00 a.m. Eastern Time to discuss its financial...

Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise

Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024

Apr 5, 2024

Pittsburgh, PA, April 05, 2024 - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella," "our," "us" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces that its abstract has been accepted for the 2024 American Society of Clinical Oncology (ASCO) meeting on May 31 through June 4 in Chicago, Illinois. Lipella’s abstract, “Intravesical local administration of pembrolizumab for treatment of bladder cancer: A novel...

Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise

Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis

Apr 3, 2024

Pittsburgh, PA, April 03, 2024 - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella," "our," "us" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced that the U.S. Food and Drug Administration (“FDA”) has granted a Type C meeting request to discuss the company’s proposed Phase-2b clinical trial design for the evaluation of LP-10, an intravesical liposomal formulation of tacrolimus, as a potential treatment for...

BioStem Technologies to Present at the 14th Annual LD Micro Invitational Conference

BioStem Technologies to Present at the 14th Annual LD Micro Invitational Conference

Apr 2, 2024

BioStem CEO, Jason Matuszewski, will present on Tuesday, April 9, 2024, at 12:30 pm ET POMPANO BEACH, FLORIDA, April 2, 2024—BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, today announced that it will present at the 14th Annual LD Micro Invitational Conference at the Sofitel New York on April 8-9, 2024. BioStem’s Chief Executive Officer, Jason...

BioStem Technologies to Present at the 14th Annual LD Micro Invitational Conference

BioStem Technologies Reports Fourth Quarter Revenue of $11.5 Million, 14-Fold YoY Increase

Apr 1, 2024

-Project Continued Growth from Sales of AmnioWrap2®- -Financial Results Conference Call and Webcast on Monday, April 1, 2024 at 4:30 pm EDT- POMPANO BEACH, FLORIDA, April 1, 2024—BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics, today reported financial results for the fourth quarter and twelve months ended December 31, 2023. Jason Matuszewski, CEO of BioStem,...

PRISM MARKETVIEW PREVIEWS ANTICIPATED FDA DRUG APPROVALS FOR 2024

Mar 25, 2024

New York, N.Y., March 25, 2024 - PRISM MarketView - Drug development is an arduous, costly and time-consuming process for the teams involved behind the scenes, and the patients anxiously awaiting breakthroughs in different disease areas. It takes 12 years on average for a company to take a drug from discovery to commercialization, and every hard-won FDA approval is a cause for celebration for researchers, companies and the end-users whose lives may be changed by these treatments. The past few...

BioStem Technologies to Present at the 14th Annual LD Micro Invitational Conference

BioStem Technologies to Report Fourth Quarter 2023 Financial Results on Monday, April 01, 2024

Mar 21, 2024

Conference Call on Monday, April 1st, at 4:30 pm ET POMPANO BEACH, FLORIDA, March 21, 2024 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics for advanced wound care, announced today that it plans to release its fourth quarter 2023 financial results post-market Monday, April 01, 2024. BioStem will host a conference call and webcast at 4:30 pm ET on Monday, April 01, 2024....

PRISM MarketView Spotlights Companies Leading the Charge in Liver Disease Treatment Following Landmark FDA Approval

PRISM MarketView Spotlights Companies Leading the Charge in Liver Disease Treatment Following Landmark FDA Approval

Mar 18, 2024

New York, N.Y., March 18, 2024 - PRISM MarketView, a leading provider of unbiased market insight and company news, today highlights the FDA’s landmark approval of Rezdiffra™ and the companies leading the charge in developing new, safe, and effective treatments for liver disease. The landmark decision has shone a light on metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic fatty liver disease, a leading cause of liver-related mortality that affects between...

PRISM MarketView Spotlights Lipella Pharmaceuticals as it Seizes Opportunities in Rare Disease

PRISM MarketView Spotlights Lipella Pharmaceuticals as it Seizes Opportunities in Rare Disease

Mar 7, 2024

New York, N.Y., March 07, 2024 - PRISM MarketView announces the release of an insightful interview with Lipella Pharmaceuticals’ CEO, Dr. Jonathan Kaufman, discussing the company's recent regulatory accomplishments and how investors stand to benefit. Lipella Pharmaceuticals was recently granted Orphan Drug Designation by the FDA for LP-410, its drug candidate for oral Graft-versus-Host Disease (GvHD) and previously received Orphan Drug Designation for LP-10 in 2023. With these nods from the...

Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise

Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical Pipeline

Mar 5, 2024

Clinical testing of LP-410 expected to commence in Q2 2024 Pittsburgh, PA, March 05, 2024 - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella," "our," "us" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces that the U.S. Food and Drug Administration (FDA) has approved an Investigational New Drug (IND) application for clinical testing of LP-410 in the treatment of oral Graft-Versus-Host Disease (GVHD). Lipella’s...

PRISM MarketView Highlights Work of Emerging Companies on Rare Disease Day

PRISM MarketView Highlights Work of Emerging Companies on Rare Disease Day

Feb 29, 2024

New York, N.Y., February 29, 2024 - PRISM MarketView, a leading provider of unbiased market insight and company news, recognizes the remarkable contributions of companies developing treatments for the 10,000 rare diseases affecting more than 30 million Americans. All areas of medicine, and all organs and body systems, are impacted by rare diseases, including rare neurological and neuromuscular diseases, metabolic, skin and bone diseases, and chromosomal disorders. Approximately 95% of rare...

Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference

Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference

Feb 20, 2024

Chief Medical Officer Dr. Michael Chancellor will discuss hemorrhagic cystitis and the company’s lead candidate, LP-10 Pittsburgh, PA, February 20, 2023 - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella," "our," "us" or the "Company") a pioneering, clinical-stage pharmaceutical company, announced today that Chief Medical Officer Dr. Michael Chancellor will present at the PropThink Digital Investor Conference’s key opinion leader (KOL) discussion on Friday, February 23, 2024, at 2 PM ET....

PRISM MarketView Marks World Cancer Day

PRISM MarketView Marks World Cancer Day

Feb 1, 2024

New York, N.Y., February 01, 2024 - PRISM MarketView, a leading provider of unbiased market insight and company news, today recognizes the tremendous contributions of companies striving to develop treatments for cancer, a complex disease driven by numerous factors. It is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, and is the second leading cause of death in the United States. To mark World Cancer Day, which will be held on February 4, PRISM MarketView...

BioStem Technologies to Present at the 14th Annual LD Micro Invitational Conference

Amniowrap2™ Product Launch Leads Year of Highlights for BioStem Technologies

Jan 30, 2024

BioStem provides a business update and highlights recent accomplishments Preliminary fourth quarter net revenues of $11.5 million and full year 2023 net revenues of $16.7 million National Pricing for Amniowrap2™ effective January 1st in all 50 states and territories POMPANO BEACH, FLORIDA, January 30, 2024 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived allografts for advanced...

Blue Water Petroleum Corp (BWPC) Develops New Battery Products

Jan 16, 2024

CHEYENNE, WY, January 16, 2024 - Blue Water Petroleum Corp’s (OTC PINK: BWPC), owned subsidiary Attimar SA, has announced the development of a new battery technology, delivering up to a twenty-five percent increase in charging capacity and up to a ten times boost in overall lifespan, compared to current leading energy storage solutions. The target markets are the automotive and industrial sectors; both requiring high capacity units that can store and deliver a relatively large amount of...

ONCOCYTE REPORTS Full Year 2023 FINANCIAL RESULTS

Oncocyte to Present at the Sequire Investor Summit in Puerto Rico

Jan 16, 2024

IRVINE, CA, January 16, 2024 - Oncocyte Corporation (NASDAQ: OCX), a precision diagnostics company, today announced that CEO Josh Riggs will be presenting a corporate overview at the upcoming Sequire Investor Summit 2024. The conference is scheduled for January 23-25, 2024 at the Condado Vanderbilt Hotel in San Juan, Puerto Rico. For more information about the Sequire Investor Summit, including registration details, please visit the official event website at https://puertorico.srax.com/ About...

PRISM MarketView Announces the Addition of Verastem to Emerging Women’s Health Index

Jan 12, 2024

New York, N.Y., January 12, 2024 - In concert with Cervical Health Awareness Month, PRISM MarketView has added Verastem, Inc., a biopharmaceutical company focused on the development and commercialization of new medicines for patients combating various types of cancer to its Emerging Women’s Health Index. Some of these cancers include breast, gynecological, colorectal and melanoma. The growing PRISM Emerging Women’s Health Index tracks small and micro-cap stocks that focus on a broad range of...

BioStem Technologies to Present at the 14th Annual LD Micro Invitational Conference

BioStem Technologies Appoints Proven Life Science Sales Leader Shawn McCarrey to Chief Commercial Officer Role

Jan 11, 2024

Mr. McCarrey brings a strong track record of success and deep experience in regenerative medicine markets POMPANO BEACH, FLORIDA, January 11, 2024 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, today announces it has appointed a proven life science sales leader, Mr. Shawn McCarrey, as Chief Commercial Officer. BioStem Technologies CEO, Jason...

PRISM MarketView Honors National Biotechnology Month with a Spotlight on Emerging Biotech Innovators

Jan 9, 2024

New York, N.Y., January 9, 2024 - In celebration of National Biotechnology Month, PRISM MarketView acknowledges the significant advancements in biotechnology since its establishment by President Clinton in 2000. This month-long celebration underscores the remarkable achievements and untapped potential of biotechnology – a field that harnesses living organisms and systems to develop pioneering products, intersecting with various scientific disciplines. Biotechnology, with its deep roots in...

Enveric Biosciences Announces EB-003 as Lead Drug Candidate for Mental Health Disorders; Stock Jumps 37%

Enveric Biosciences Announces EB-003 as Lead Drug Candidate for Mental Health Disorders; Stock Jumps 37%

Dec 28, 2023

New York, December 28, 2023 - Enveric Biosciences (NASDAQ: ENVB), a biotechnology company specializing in developing novel treatments for mental health disorders, has named EB-003 as the lead candidate from its EVM301 Series. This series targets depression, anxiety, and addiction disorders. The selection of EB-003 is a key milestone for Enveric, transitioning the company from a discovery phase to a drug development phase. EB-003 is chosen for its potential to...

PRISM Emerging MedDevices Mover Spotlight: Milestone Scientific Inc. (MLSS)

PRISM Emerging MedDevices Mover Spotlight: Milestone Scientific Inc. (MLSS)

Dec 27, 2023

New York, December 27, 2023 - Milestone Scientific Inc. (NYSE:MLSS) has established itself in the field of biomedical technology with its focus on advanced injection technologies for medical and dental applications. The company holds over 19 US patents and 133 foreign patents. Its dental product, the Single Tooth Anesthesia System (STA), has received FDA and CE marketing clearance in more than 50 countries. The STA system utilizes computer-assisted technology for precise and consistent...

Immutep Advances Towards Phase III Trial for Lung Cancer Treatment with Positive Regulatory Feedback

Immutep Advances Towards Phase III Trial for Lung Cancer Treatment with Positive Regulatory Feedback

Dec 27, 2023

New York, December 27, 2023 - Immutep Limited (ASX: IMM; NASDAQ: IMMP), a trailblazing clinical-stage biotechnology company, has announced encouraging news from the Paul-Ehrlich-Institut (PEI), part of the Committee for Medicinal Products for Human Use (CHMP). This announcement marks a significant step forward in the company’s development of novel LAG-3 immunotherapies for cancer and autoimmune diseases. https://prismmarketview.com/companies/immutep-limited/#news Marc Voigt, CEO of Immutep...

Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones Accomplished

Dec 20, 2023

-Lipella Granted Two Orphan Drug Designations by FDA- Pittsburgh, PA, December 20, 2023 - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella," "our," "us" or the "Company") a pioneering, clinical-stage pharmaceutical company, celebrates its first anniversary as a publicly traded entity. Based in Pittsburgh, PA, the Company has made substantial strides over the past year, achieving critical milestones and advancing its pipeline with three clinical indications and two orphan drug designations...